Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review

Karlsen, Emma-Anne; Kahler, Sam; Tefay, Joan; Joseph, Shannon R.; Simpson, Fiona

doi:10.3390/cells10051206

Open AccessReview

Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review

by

Emma-Anne Karlsen

^1,2,3,*

,

Sam Kahler

³

,

Joan Tefay

^3,4,

Shannon R. Joseph

¹ and

Fiona Simpson

¹

Simpson Laboratory, The University of Queensland Diamantina Institute, Woolloongabba, Brisbane 4102, Australia

²

Department of General Surgery, Mater Hospital Brisbane, South Brisbane 4101, Australia

³

Faculty of Medicine, The University of Queensland, St Lucia 4067, Australia

⁴

Department of General Surgery, Redland Hospital, Cleveland 4163, Australia

^*

Author to whom correspondence should be addressed.

Cells 2021, 10(5), 1206; https://doi.org/10.3390/cells10051206

Submission received: 19 April 2021 / Revised: 29 April 2021 / Accepted: 6 May 2021 / Published: 14 May 2021

(This article belongs to the Special Issue EGFR Signaling in Non-Small-Cell Lung Cancer: From Molecular Mechanisms to Therapeutic Opportunities)

Download

Browse Figure

Versions Notes

Abstract

Globally, lung cancer is the leading cause of cancer-related death. The majority of non-small cell lung cancer (NSCLC) tumours express epidermal growth factor receptor (EGFR), which allows for precise and targeted therapy in these patients. The dysregulation of EGFR in solid epithelial cancers has two distinct mechanisms: either a kinase-activating mutation in EGFR (EGFR-mutant) and/or an overexpression of wild-type EGFR (wt-EGFR). The underlying mechanism of EGFR dysregulation influences the efficacy of anti-EGFR therapy as well as the nature of resistance patterns and secondary mutations. This review will critically analyse the mechanisms of EGFR expression in NSCLC, its relevance to currently approved targeted treatment options, and the complex nature of secondary mutations and intrinsic and acquired resistance patterns in NSCLC.

Keywords: epidermal growth factor receptor; non-small cell lung cancer; drug resistance; tyrosine kinase inhibitor; monoclonal antibody

Share and Cite

MDPI and ACS Style

Karlsen, E.-A.; Kahler, S.; Tefay, J.; Joseph, S.R.; Simpson, F. Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. Cells 2021, 10, 1206. https://doi.org/10.3390/cells10051206

AMA Style

Karlsen E-A, Kahler S, Tefay J, Joseph SR, Simpson F. Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. Cells. 2021; 10(5):1206. https://doi.org/10.3390/cells10051206

Chicago/Turabian Style

Karlsen, Emma-Anne, Sam Kahler, Joan Tefay, Shannon R. Joseph, and Fiona Simpson. 2021. "Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review" Cells 10, no. 5: 1206. https://doi.org/10.3390/cells10051206

APA Style

Karlsen, E.-A., Kahler, S., Tefay, J., Joseph, S. R., & Simpson, F. (2021). Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. Cells, 10(5), 1206. https://doi.org/10.3390/cells10051206

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI